Enstilar® (calcipotriene/betamethasone dipropionate) – Expanded indication
July 31, 2019 - Leo Pharma announced the FDA approval of Enstilar (calcipotriene/betamethasone dipropionate) topical foam, for the topical treatment of plaque psoriasis in patients 12 years of age and older.
Download PDF
